IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.
复制标题
DOI：
10.1097/qad.0000000000000052
复制
发表时间：
2014-01-02
期刊：
影响因子：
--
通讯作者：
Martinez, Miguel Angel
中科院分区：
文献类型：
--
作者：
Franco, Sandra;Aparicio, Ester;Martinez, Miguel Angel
最近发现一种新的瞬时诱导区域（干扰素-λ 4蛋白; IFNL 4），其在IFNL 3（IL 28 B）上游具有二核苷酸变体ss 469415590（TT或DeltaG），与丙型肝炎病毒（HCV）清除相关。为了确定IFLN 4 ss 469415590变异对HCV/HIV-1合并感染患者对基于IFN的治疗的HCV应答的影响，对来自我们诊所的207名患者的队列进行ss 469415590基因分型。治疗失败发生在77%的轻微DeltaG等位基因携带者和48%的非携带者中，表明DeltaG等位基因与治疗失败密切相关。重要的是，多变量logistic分析显示ss 469415590基因型比rs 12979860基因型更能预测治疗失败。
A new transiently induced region (interferon-lambda 4 protein; IFNL4) harbouring a dinucleotide variant ss469415590 (TT or DeltaG), upstream of IFNL3 (IL28B), was recently found to be associated with hepatitis C virus (HCV) clearance. To determine the effect of IFLN4 ss469415590 variation on the HCV response to IFN-based therapy in HCV/HIV-1 coinfected patients, ss469415590 was genotyped in a cohort of 207 patients from our clinic. Treatment failure occurred in 77% of minor DeltaG-allele carriers versus 48% of noncarriers, indicating that the DeltaG allele was strongly associated with treatment failure. Importantly, multivariate logistic analysis revealed that ss469415590 genotype was a better predictor of treatment failure than rs12979860.